MRK Stock Recent News
MRK LATEST HEADLINES
Germany's Merck on Friday further its forecast for the group and said it now expects net sales to be between 20.7 billion euros ($22.49 billion) and 22.1 billion euros for 2024.
Merck (NYSE: MRK) will report its Q2 2024 results on Tuesday, July 30. We expect the company to post revenue of $15.9 billion and adjusted earnings of $2.20, slightly ahead of the street estimates.
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Merck & Co will announce Q2 2024 earnings on July 30th. Merck's share price has risen 65% in the past 3 years, driven by the success of Keytruda, the world's best-selling drug. Keytruda revenues were up 25% year-on-year in Q1 2024, contributing nearly 45% of Merck's total revenues last quarter.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Fourth-Quarter 2024 Dividend.
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports second-quarter 2024 earnings.
Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck said on Tuesday its respiratory syncytial virus (RSV) drug met the safety and efficacy goals in a mid- to late- stage study testing it in infants.
Merck (MRK) closed at $125.69 in the latest trading session, marking a -0.06% move from the prior day.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.